Tonix Pharmaceuticals doses first patient in MGH-Led FOCUS study of intranasal Oxytocin therapy

Tonix Pharmaceuticals Holdings CEO Dr. Seth Lederman joined Steve Darling from Proactive to announce that the first patient has been dosed in the investigator-initiated FOCUS study at Massachusetts General Hospital. The study is focused on adult patients with arginine-vasopressin deficiency (AVP-D)—a rare endocrine disorder formerly known as central diabetes insipidus—that is now understood to be linked to oxytocin deficiency and adverse mental health outcomes. Dr. Lederman explained that oxytocin, commonly known as the “bonding hormone,” plays a critical role in regulating mood, social behavior, and emotional wellbeing. Emerging evidence suggests that individuals with AVP-D suffer from low oxytocin levels, contributing to symptoms such as anxiety, depression, and socioemotional impairment. The FOCUS study is designed as a randomized, double-blind, placebo-controlled crossover pilot trial. It will assess Tonix’s investigational intranasal potentiated oxytocin formulations—TNX-1900 (24 IU) and TNX-2900 (6 IU)—to determine their impact on mood and social functioning markers in patients with AVP-D. In addition to the single-dose evaluations, the study will include an exploratory two-week treatment phase to assess longer-term effects on mental health and quality-of-life outcomes. Dr. Lederman noted that Tonix is providing study support and that results from this research may inform the broader development of oxytocin replacement therapies for neuropsychiatric and endocrine-related disorders. The successful dosing of the first patient marks a significant milestone in Tonix’s ongoing efforts to advance innovative, mechanism-driven therapies for complex disorders with unmet medical needs. #proactiveinvestors #tonixpharmaceuticalsholdingcorp #nasdaq #tnxp #Biotech #MPOXVaccine #Smallpox #TNX801 #VaccineDevelopment #ClinicalTrials #PharmaceuticalNews #MedicalResearch #WHO #GlobalHealth #InfectiousDiseases #Biopharma #ProactiveInvestors

Gunnison Copper Corp SVP and CFO Craig Hallworth joined Steve Darling from Proactive to share exciting results from the company’s ongoing High-Value-Add Work Program, which is evaluating the commercial potential of limestone located within the planned Gunnison Open Pit mine in southeast Arizona. The assessment has revealed that a substantial portion of the limestone—currently classified as waste material in the existing mine plan—meets the specifications for a range of industrial end-use markets, including cement production, agricultural lime, and premium paper filler, paint, and coatings applications. Hallworth explained that these findings represent a significant opportunity to generate additional revenue streams from materials previously slated for disposal. “Our initial results suggest strong potential to convert what was once waste into high-value commercial products,” he said. The company plans to expand sampling coverage beyond the initial 883 feet to enhance statistical confidence across the entire open pit area. Upcoming test work will focus on verifying product quality and consistency to meet cement, ag-lime, and premium filler-grade standards. In tandem, Gunnison Copper will explore mine plan optimization and materials-handling trade-offs to identify feasible pathways to market. These efforts will feed into a broader evaluation of logistics, permitting, and commercialization strategies, including potential marketing partnerships and offtake agreements. The insights from this work will be incorporated into the company’s updated Preliminary Economic Assessment, targeted for Q1 2026, and will inform the scope of the forthcoming Pre-Feasibility Study. Hallworth emphasized that this initiative reflects Gunnison Copper’s commitment to maximizing resource efficiency and unlocking hidden value across its asset base. #proactiveinvestors #gunnisoncoppercorp #tsx #gcu #otcqb #gcumf #CopperMining #USMining #CopperProject #CopperMining #GunnisonCopper #NutonTechnology #USMining #CriticalMinerals #CopperProduction #MiningStocks #NaturalResources #ElectricEconomy #CopperPrices #FreeCashFlow #JohnsonCampMine #linstone #steel

Vaultz Capital PLC (AQSE:V3TC, OTCQB:VZTCF) CEO Eric Benz talked with Proactive's Stephen Gunnion about the company's admission to trading on the OTCQB Venture Market in the United States. Benz said joining the OTCQB was an important milestone for Vaultz Capital as it enables access to a wider investor base and deeper liquidity. “Being live with OTCQB really is important for us for a couple of different reasons,” he explained. “This allows us to open ourselves up to a US-focused investor base, which is going to fuel the Treasury in my opinion.” He noted that the move will help the company progress several internal projects that had been paused while awaiting the listing. One of the main initiatives is a full-scale rebrand, including a new name, website, and visual identity aimed at improving positioning as Vaultz scales its operations and targets new markets. Benz also emphasised the strategic importance of listing in both the US and Frankfurt markets. He said that Frankfurt processes over €5 billion in trades daily and, combined with the OTCQB in the US, offers Vaultz Capital broader investor visibility and capital access. On the topic of Bitcoin, Benz reaffirmed the company’s strong stance. “We are long Bitcoin. We're always going to be buying Bitcoin. Bitcoin is in our blood,” he stated, adding that recent price fluctuations have no impact on Vaultz’s strategy. For more interviews like this, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for future updates. #VaultzCapital #EricBenz #OTCQB #USMarket #InvestorAccess #CapitalMarkets #BitcoinStrategy #Rebrand #FrankfurtListing #CryptoFinance

Medicus Pharma CEO Dr Raza Bokhari joined Steve Darling from Proactive to announce a major clinical milestone — the enrollment of the first patient in the company’s SKNJCT-004 Phase 2 clinical trial in the United Arab Emirates (UAE). The study aims to evaluate a non-invasive treatment for basal cell carcinoma (BCC), the most common form of skin cancer. The multi-center, double-blind, placebo-controlled trial will enroll 36 patients across six leading medical institutions in the UAE, including Cleveland Clinic Abu Dhabi, Sheikh Shakbout Medical City, Burjeel Medical City, Rashid Hospital, Clemenceau Medical Center, and American Hospital of Dubai. Dr. Bokhari explained that the study will assess the efficacy and safety of two dose levels of Medicus Pharma’s proprietary D-MNA (drug-coated microneedle array) compared to a placebo control. Participants will be randomized into three groups, a placebo-controlled group receiving P-MNA, a low-dose group receiving 100μg of D-MNA, and a high-dose group receiving 200μg of D-MNA. The 200μg dose represents the maximum level previously used in the company’s successful Phase 1 safety and tolerability trial (SKNJCT-001), completed in March 2021. Dr. Bokhari emphasized that this next phase marks a significant step forward for Medicus Pharma’s mission to develop non-invasive dermatological treatments that can potentially eliminate the need for surgical excision in certain skin cancer cases. With recruitment underway and multiple top-tier hospitals participating, the SKNJCT-004 study positions Medicus Pharma at the forefront of innovative, patient-friendly oncology solutions in the Middle East and beyond. #proactiveinvestors #nasdaq #mdcx #tsxv #mdcx #pharma #Biotech #CancerTreatment #ClinicalTrials #FDAApproval #SkinCancer #HealthcareInnovation #Investing #MedicalResearch #SkinCancer #BasalCellCarcinoma #BiotechNews #CancerResearch #UAEHealth #NonInvasiveTherapy #Doxorubicin #ClinicalTrials #HealthcareInnovation

Anteris Technologies CEO Wayne Paterson joined Steve Darling from Proactive to share a major milestone in the company’s development of DurAVR®, its groundbreaking aortic valve replacement technology designed to transform treatment for patients suffering from aortic stenosis — a fatal heart disease for which no pharmacotherapy options exist. Paterson explained that DurAVR® was designed from the ground up following extensive collaboration with leading cardiologists and cardiac surgeons. The result is a biomimetic, balloon-expandable valve engineered to replicate natural valve anatomy and physiology — a radical advancement over traditional bioprosthetic devices. “We developed one that is physiologically and anatomically correct. It gives you pre-disease mean gradients — that’s been established across 130 patients now,” Paterson said, underscoring the valve’s ability to restore near-normal cardiac function. The company recently secured its first regulatory clearance in Europe, paving the way for broader international approvals in the near term. This clearance allows Anteris to initiate its global PARADIGM pivotal trial, which will evaluate DurAVR® across low-, medium-, and high-risk patient groups. The study will also feature a valve-in-valve registry and target a non-inferiority primary endpoint, aligning with global regulatory pathways for approval. Paterson highlighted that medical device trials carry far less risk than pharmaceutical studies, with Anteris already demonstrating highly consistent patient outcomes. The company has also laid significant groundwork for clinical expansion, including site preparation and an upcoming investigator meeting at the TCT conference in San Francisco. Built on Anteris’ proprietary ADAPT® tissue platform, DurAVR® has shown 20–30% clinical superiority in objective performance metrics. Paterson noted that the company has achieved what physicians have long demanded: clinical superiority combined with balloon-expandable delivery. “This milestone moves us closer to our goal of redefining valve replacement therapy,” Paterson said. “DurAVR® represents the future of aortic valve technology — designed by physicians, built for patients, and proven by data.”

Argentina Lithium CEO Nikolaos Cacos joined Steve Darling from Proactive to unveil the company’s first-ever Mineral Resource estimate for its Rincon West lithium brine project located in Salta Province, Argentina—a key step forward in advancing the company’s lithium portfolio within the heart of the “Lithium Triangle.” The inaugural resource estimate, completed for the West Block properties—including the Villanoveño II and Rinconcita II mining concessions covering 2,931 hectares—marks a significant milestone for Argentina Lithium. The estimate excludes the Paso de Sico concessions to the north, which add another 3,742.9 hectares of prospective ground at the Rincon Salar, representing future upside for the project. The resource was defined through 14 exploration boreholes totaling 4,823.2 metres of diamond drilling and one production well extending 470 metres. Based on this work, the company reports: Measured and Indicated Resources: 0.15 km³ of brine averaging 296 mg/L lithium, equivalent to 238,000 tonnes of Lithium Carbonate Equivalent (LCE). Inferred Resources: 0.08 km³ of brine averaging 216 mg/L lithium, equivalent to 64,000 tonnes of LCE. Cacos emphasized that the results demonstrate Rincon West’s potential as a scalable, high-quality lithium asset within one of the world’s most prolific brine districts. “This maiden resource lays a solid foundation for our next phase of development as we work toward building a sustainable, high-value lithium operation capable of generating long-term returns,” he said. As the company moves ahead with Preliminary Economic Assessment (PEA) studies and evaluates advanced direct lithium extraction (DLE) technologies, exploration teams will also target deeper drilling below the current resource boundary—where geologic data indicates open mineralization at depth and significant room for expansion. With a strong technical foundation and growing land position, Argentina Lithium is positioning Rincon West as a key contributor to Argentina’s emerging lithium supply chain, supporting the accelerating global demand for electric vehicle and energy storage materials. #proactiveinvestors #argentinalithium&energycorp #tsxv #lit #otcqx #lilif #proactiveinvestors #argentinalithium&energycorp #tsxv #lit #otcqx #lilif

Anthony Ginsberg, CEO of GinsGlobal Index Fund, recently spoke with Steve Darling from Proactive to discuss recent updates to the firm’s Tech Megatrend ETF, a globally diversified fund designed to capture growth across the world’s most transformative technology themes. Ginsberg explained that the ETF maintains a global benchmark with just over 50% exposure to the U.S. and nearly 20% to Asia, including China and Japan. The fund spans ten key technology subthemes such as cybersecurity, cloud computing, artificial intelligence, and blockchain, providing investors with broad access to multiple innovation-driven sectors. In a significant enhancement, the ETF has now added quantum computing and defense technology to its portfolio. “Quantum is really changing the speed of innovation across industries—from financial services and pharmaceuticals to R&D—helping companies find faster, smarter, and more cost-effective solutions,” Ginsberg said. The fund now includes five quantum-focused companies, each with a minimum market cap of $200 million. The addition of defense technology reflects a growing trend among governments to allocate more of their defense budgets toward cybersecurity and digital defense infrastructure. Ginsberg noted that 1.5% of NATO countries’ defense GDP is now being directed toward defense technology initiatives, underscoring the increasing convergence of tech innovation and national security. When discussing performance, Ginsberg pointed to blockchain as the ETF’s top performer in 2025 so far, posting gains exceeding 50%, followed by cybersecurity and digital entertainment, each returning around 25–30%. He also highlighted the ETF’s diversified structure, distinguishing it from typical U.S.-centric tech funds. “We only have about a 6% weighting in the ‘Magnificent Seven,’” Ginsberg noted, emphasizing the ETF’s broader exposure across emerging innovators and lower concentration risk within its top holdings. With these updates, GinsGlobal’s Tech Megatrend ETF continues to position itself at the forefront of the global technology evolution, offering investors access to high-growth sectors driving the next wave of digital transformation. #TechMegatrendETF, #AnthonyGinsberg, #FourthIndustrialRevolution, #AI, #Cybersecurity, #CloudComputing, #SocialMedia, #FutureCars, #Robotics, #InterestRateCuts, #Diversification, #GlobalHoldings, #Nasdaq,

Pinnacle Silver and Gold CEO Robert Archer joined Steve Darling from Proactive to announce the appointment of Carlos Castro Villalobos as Project Manager for the company’s El Potrero gold-silver project in Durango, Mexico. The addition of Castro—an accomplished Mining Engineer with more than 45 years of experience building and operating mines across Mexico—marks a major step forward in advancing El Potrero toward production. Castro’s extensive background includes leadership roles with several of Mexico’s most respected mining companies, such as Peñoles, Luismin, Great Panther, and First Majestic Silver. Over his career, he has held senior positions ranging from Mine Superintendent to General Manager, and notably, while with Rochester Resources, he successfully oversaw the construction of a 300-tonne-per-day processing plant in just seven months—a skill set that will be especially valuable as Pinnacle looks to accelerate development at El Potrero. Archer also confirmed that Jorge Ortega, the Qualified Person (QP) for the project and author of the NI 43-101 technical report, continues in his role as Exploration Manager. Ortega is actively supervising a geological team that has already collected more than 1,000 surface and underground samples, significantly enhancing the company’s understanding of the high-grade, low-sulphidation epithermal gold-silver system at the project. Located in western Mexico, El Potrero is strategically positioned just 35 kilometres from four producing mines, including the 4,000-tonne-per-day Ciénega Mine. Pinnacle will earn an initial 50% interest upon the commencement of production, with the potential to increase ownership to 100%, subject to a 2% net smelter return. #proactiveinvestors #pinnaclesilverandgoldcrp #robertarcher #tsxv #pinn #otc #psgcf #PinnacleSilverAndGold #MiningMexico #SilverMining #GoldMining #JuniorMiners #MiningExploration #ElPotrero #MineRestart #PreciousMetals #MiningStocks #ResourceSector

KEFI Gold and Copper PLC (AIM:KEFI, OTC:KFFLF) executive chairman Harry Anagnostaras-Adams talked with Proactive's Stephen Gunnion about the company’s significant progress in securing funding and advancing development at the Tulu Kapi gold project in Ethiopia. Anagnostaras-Adams confirmed the company has secured a US$240 million debt package, marking a major milestone. With all regulatory and governmental approvals now in place, KEFI is focused on closing the equity component to trigger full project drawdown. He noted, “We’ve allocated about a month to do that, to close that off, call the shareholders meeting to ratify everything. And we're away.” Construction preparations are already underway. KEFI has worked with the Ethiopian government to establish essential infrastructure and security, while engineering firm Lycopodium has been mobilised for procurement and construction. Community resettlement will begin shortly, followed by phased development throughout 2026 and into 2027. Production is targeted for late 2027, with gold commissioning expected by the end of that year. Anagnostaras-Adams highlighted that, at conservative gold prices, the project could deliver **over $1 billion in net cash flow** over seven years, with potential for much more if prices remain high. He concluded: “It’s arguably the best margin gold project going into development in Africa today.” For more updates from KEFI Gold and Copper, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe, and turn on notifications for the latest news and interviews. #KEFI #GoldMining #Copper #EthiopiaMining #MiningInvestment #GoldProject #TuluKapi #ResourceDevelopment #GoldProduction #JuniorMining #MiningAfrica #MiningNews #ProactiveInvestors

Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) CEO Dr Eric Leire talked with Proactive's Stephen Gunnion about the company's latest milestone – the granting of its second European patent, which he says is a key part of Genflow’s intellectual property strategy in the longevity and metabolic disease space. Leire explained that the patent strengthens the company’s position by providing protection not only for the composition of matter but also for specific methods of use, all focused around Sirtuin-6, a core element in the company’s technology platform. He stated, “We’re building a layer portfolio that combines property, construct, delivery method, and specific applications for human health.” The new patent covers a variant for NASH (non-alcoholic steatohepatitis), but Leire noted that the Sirtuin-6 platform has broader relevance for multiple age-related diseases, including glaucoma, sarcopenia, and other metabolic conditions. He emphasised that strong IP is essential for entering into licensing and partnership discussions with pharmaceutical companies, adding, “Without strong IP protection, there's no potential deal with pharma.” Looking ahead, Leire said that Genflow is prioritising its ongoing dog study and will soon undertake a strategic review to determine which of the many potential indications to pursue further. Visit Proactive's YouTube channel for more company interviews. Don’t forget to like this video, subscribe to the channel, and enable notifications so you never miss an update. #GenflowBiosciences #Longevity #BiotechNews #Sirtuin6 #MetabolicDisease #BiotechInvesting #NASH #IPStrategy #PharmaPartnerships #AgeRelatedDiseases